CABFIDENCE CAB+RPV LA Study: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047)

12/06/2025
23/07/2026
EU PAS number:
EUPAS1000000616
Study
Ongoing
Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Drug utilisation
Effectiveness study (incl. comparative)
Evaluation of patient-reported outcomes
Other
Safety study (incl. comparative)

If ‘other’, further details on the scope of the study

Persistence, Adherence

Data collection methods

Combined primary data collection and secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medicinal product name

Medicinal product name, other

Cabenuva

Study drug International non-proprietary name (INN) or common name

CABOTEGRAVIR
RILPIVIRINE

Anatomical Therapeutic Chemical (ATC) code

(J05AJ04) cabotegravir
cabotegravir
(J05AG05) rilpivirine
rilpivirine

Medical condition to be studied

Human immunodeficiency virus transmission
Population studied

Short description of the study population

People living with HIV (PLWH) aged 18 years and older were included in the study

Age groups

  • Adult and elderly population (≥18 years)
    • Adults (18 to < 65 years)
      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)
      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Estimated number of subjects

2.000
Study design details

Study design

This observational study will assess the utilization patterns, adherence, persistence, discontinuation, virologic effectiveness, and patient-reported outcomes of CAB+RPV LA in a real-world clinical setting.

Main study objective

• To describe baseline demographics and clinical characteristics among individuals receiving CAB+RPV LA
• To assess the persistence, discontinuation, and adherence among individuals receiving CAB+RPV LA
• To assess virologic effectiveness among individuals receiving CAB+RPV LA
• To assess factors associated with confirmed virologic failure (CVF) among individuals receiving CAB+RPV LA regimen

Outcomes

• Persistence
• Discontinuation
• Adherence
• Virologic effectiveness
• Resistance
• ART regimen after discontinuation /CVF
• Safety outcomes (ISR and HSR)
• HIV Health-related quality of life
• Baseline adherence
• Social Determinants of health
• Treatment satisfaction
• Treatment preference
• Treatment-related worries and stigma, and benefits
• Reasons for initiating CAB+RPV LA
• Reasons for discontinuing CAB+RPV LA
• Reasons for missed injection(s)

Data analysis plan

Baseline characteristics and outcomes will be described using counts and relative frequencies for categorical variables. Continuous variables will be summarized using summary statistics (means, standard deviations, medians, minimums, maximums, and quartiles 1 and 3). For event outcomes assessed at any point during follow-up, incidence rates will be estimated using unadjusted Poisson regression, accounting for person-time since index (i.e., first CAB+RPV LA injection) where appropriate. Additional analytic approaches may also be considered (e.g., Kaplan-Meir estimator/curve). Analyses will be stratified by BMI (< 30 kg/m^2 vs. ≥ 30 kg/m^2), age (18-49, 50-64, ≥ 65 years), sex assigned at birth (female, male) and race and ethnicity, sex/race and country, if sample sizes allow, at initiation of CAB+RPV LA regimen. Factors associated with CVF will be assessed using a logistic regression model. The number and proportion of participants with history of resistance to INSTI or NNRTI classes and INSTI and/or NNRTI RAMs at discontinuation/CVF with results will be described. Subsequent regimen after discontinuation/CVF and virologic outcomes will be assessed. Participant surveys will be summarized descriptively for item and summary score (where applicable). The World Health Organization Quality of Life-Human Immunodeficiency Virus BREF (WHOQOL-HIV BREF), HIVTSQs, and HIVTSQc will be scored according to instrument scoring guidelines and derived scores will be summarized descriptively.